Stendhal (officially Específicos Stendhal, S.A. de C.V.) is a private Mexican pharmaceutical company established in 1974 that specializes in the identification, development, and commercialization of innovative and high-specialty medications in Latin America.

Core Business and Therapeutic Areas

The company focuses on innovative medicines rather than generics, specifically targeting high-tech treatments for critical conditions. Its primary therapeutic areas include:

Specialty Medicines:
HIV/AIDS (antiretrovirals), anti-infective diseases, and neuroscience.

Emerging Portfolios:
Cardiovascular, metabolic diseases, and oncology (through alliances with partners like Baxter).

Orphan and Rare Diseases:
Leader in orphan drug therapies, having signed licenses with 10 business partners in 2021 specifically for rare diseases.

Primary Care:
Distribution and marketing of primary care products across Mexico, Central America, and the Caribbean.

Operations and Infrastructure

Stendhal operates as a regional powerhouse with a physical presence in 14 countries across Latin America.

Headquarters:
Located in Mexico City, Mexico.

Manufacturing:
Maintains a specialized plant in the State of Mexico certified by COFEPRIS (NOM-059-SSA1-2015) and ISO 9001:2015.

Services:
Offers secondary packaging services for oral solids, injectables, and cold chain medications for national and international clients.

Logistics:
Distinguished for its advanced market knowledge and sophisticated cold chain storage systems.

Corporate Governance and Compliance
Acquired by a group of Mexican investors in 1997, the company transitioned into a socially committed organization with a heavy emphasis on ethics.

Governance:
Led by a Board of Directors consisting of seven members (four proprietary and three independent).

Compliance:
Features a dedicated “Total Compliance Team” that reports directly to the Board, ensuring adherence to anti-corruption, data protection, and economic competition laws.

Awards:
Recipient of the transparency award from CETIFARMA (2010) and an ethics award from CONCAMIN (2012).

Financial and Personnel Statistics

Revenue:
Estimated at approximately $51.5 million.

Workforce:
Employs between 182 and 230 people directly, though some estimates for the broader group range up to 500.

Strategic Alliances:
A key part of its business model involves partnering with global innovators like Gilead Sciences Inc. to bring advanced therapies to the Latin American market.